Samsung Biologics Sets New Green Standard with Validated Carbon Data

INCHEON, South Korea – February 06, 2026 – In a move that signals a significant shift toward greater environmental accountability in the biopharmaceutical industry, Samsung Biologics announced today that its Product Carbon Footprint (PCF) system has received independent validation from Det Norske Veritas (DNV), a globally respected assurance and risk management provider. The validation confirms that the company's method for calculating the carbon footprint of its manufactured products complies with rigorous international standards, setting a new benchmark for transparency in a sector under increasing pressure to decarbonize.

This development provides the contract development and manufacturing organization's (CDMO) clients—many of them major pharmaceutical firms—with reliable, consistent, and verifiable data on the environmental impact of their outsourced manufacturing. As the global healthcare industry grapples with its substantial carbon footprint, this level of granular data is becoming a critical tool for companies striving to meet ambitious net-zero targets.

A New Benchmark for Environmental Accountability

The validation by Norway-based DNV confirms that Samsung Biologics' PCF calculation methodology adheres to both ISO 14067 and PAS 2050. These are not just acronyms; they represent the gold standard for quantifying the greenhouse gas emissions associated with a product's entire life cycle. ISO 14067 provides a globally recognized framework for ensuring carbon footprint calculations are consistent and transparent, while PAS 2050, developed by the British Standards Institution, offers a detailed methodology for assessing the life cycle emissions of goods and services.

DNV's rigorous assessment scrutinized the entire system, from data input and conversion methods to the final output, verifying that the underlying assumptions and calculations are sound and align with accepted global practices. This third-party endorsement elevates the company's claims beyond corporate self-declaration, providing an auditable and credible foundation for its environmental reporting. For an industry where trust and verification are paramount, this independent stamp of approval is a powerful differentiator.

"Achieving independent validation of our PCF system reflects the rigor and transparency of the carbon data we provide to clients," said John Rim, President and CEO of Samsung Biologics, in the company's official announcement. "As sustainability considerations continue to shape decision-making across the biopharmaceutical industry, we believe this system enables constructive collaboration with our partners."

Empowering Pharma's Push for Net-Zero

The strategic importance of this validation lies in its direct impact on the pharmaceutical industry's most significant environmental challenge: Scope 3 emissions. These indirect emissions, which occur in a company's value chain, often account for over 70%, and in some cases more than 90%, of a pharmaceutical company's total carbon footprint. Manufacturing outsourced to CDMOs like Samsung Biologics is a major contributor to these Scope 3 figures.

Until now, accurately measuring these upstream emissions has been a persistent challenge, often relying on industry averages and estimates rather than precise, product-specific data. By providing validated PCF data, Samsung Biologics empowers its clients to move beyond estimation to accurate measurement. This allows pharmaceutical companies to more precisely report their own environmental performance, identify carbon 'hotspots' in their supply chain, and make more informed decisions when designing and manufacturing new medicines.

This capability is arriving at a critical time. Investors are increasingly using ESG (Environmental, Social, and Governance) metrics to evaluate corporate risk and performance, while regulators, particularly in the European Union, are introducing stricter rules around environmental claims and supply chain transparency. Pharmaceutical companies are now cascading these pressures down to their suppliers, demanding hard data on everything from carbon emissions to water usage. CDMOs that can provide this verified data are positioned to become preferred partners in an increasingly green-conscious supply chain.

From Platinum Ratings to Product-Level Proof

Samsung Biologics is no stranger to sustainability accolades, having recently earned a Platinum rating from EcoVadis, placing it in the top one percent of companies evaluated for sustainability management. However, the PCF system validation represents a strategic evolution from broad, corporate-level assessments to specific, auditable, product-level proof. While a Platinum rating signifies a robust overall sustainability management system, the DNV validation provides tangible evidence of the carbon impact of individual products manufactured in its facilities.

This move directly addresses the growing skepticism around 'greenwashing,' where companies make broad environmental claims without substantiated data. By opening its carbon accounting methodology to third-party scrutiny, the company is demonstrating a deeper commitment to quantifiable and verifiable environmental impact. This level of transparency builds a stronger foundation of trust with clients and stakeholders who are increasingly sophisticated in their evaluation of corporate sustainability efforts.

This validated framework not only enhances external reporting but also provides invaluable internal insights. A detailed understanding of the carbon footprint at each stage of the complex biomanufacturing process allows the company to identify opportunities for greater efficiency, process optimization, and targeted emission reduction initiatives. This can lead to long-term operational improvements and cost savings, proving that sustainability and business performance can be mutually reinforcing.

Ripples Across the Biopharmaceutical Value Chain

As one of the world's largest CDMOs, with a massive and expanding biomanufacturing capacity, Samsung Biologics' actions carry significant weight across the industry. By establishing this high bar for carbon transparency, the company is effectively challenging its competitors to follow suit. This could accelerate the adoption of rigorous PCF accounting across the entire CDMO sector, transforming what is currently a competitive advantage into a new industry standard.

For the broader pharmaceutical industry, this shift toward data-driven environmental accountability is a crucial step on the path to decarbonization. The availability of reliable product-level carbon data from manufacturing partners is a foundational requirement for any credible net-zero strategy. As more suppliers adopt these practices, the entire value chain becomes more transparent, enabling a more collaborative and effective approach to reducing the sector's overall environmental impact.

The validation of this system is more than just a technical achievement for a single company; it represents a tangible step toward a future where the environmental cost of producing life-saving medicines is as rigorously measured and managed as their quality and efficacy.